How multidisciplinary teams (MDTs) work in practice in the management of advanced prostate cancer: A survey of oncologists and urologists in the UK

SummaryObjectiveTo determine the management practices for advanced prostate cancer amongst oncologists and urologists in the UK and assess the involvement of multidisciplinary teams.MethodsUsing a postal and email questionnaire, 51 oncologists and 63 urologists who treat patients with advanced prostate cancer were surveyed in the UK. The questions sought opinions on the role and responsibilities of oncologists and urologists in management decisions, and gave three hypothetical cases to gain insights into current management practices.ResultsAlthough most respondents stated that management decisions in advanced prostate cancer were taken jointly by oncologists and urologists, most oncologists expected the sole responsibility to lie within their own specialty. In contrast, 70% of urologists recognised a need for joint responsibility for such decisions. There was no consensus on a clear definition of hormone-refractory prostate cancer (HRPC) but a view that castration-resistant prostate cancer should replace HRPC. There was greater agreement on the management decisions taken by oncologists and urologists in the hypothetical cases.ConclusionWithin an environment where treatment options for advanced prostate cancer continue to evolve, it is important that management approaches are considered by the multidisciplinary team with a focus on the patient's individual needs and circumstances.